While many neurodegenerative diseases have been linked to causative proteins, controversy remains. When does a protein contribute to disease through gain of function (GOF), and when is it via loss of function (LOF)? While the interpretation (if not the molecular details) of pathological LOF is generally straightforward, the etiology behind a GOF can be more obscure. A GOF can be a novel property that emerges in a disease-associated protein, or it might result from an enhancement of one or more of the protein's normal functions to toxic levels.
Monogenic diseases offer tractable models to examine the nature of a GOF. Two papers in this issue of Neuron seek to do just this by exploring in vivo models of polyglutamine (polyQ) diseases. PolyQ diseases include at least nine neurodegenerative diseases caused by a pathological expansion of CAG repeats in the coding regions of different genes (Orr and Zoghbi, 2007) . These diseases vary remarkably in the susceptibility of specific brain and spinal cord regions, and together they represent the most common cause of inherited neurodegenerative disease.
Direct toxicity of the polyQ stretch has been hypothesized as a common mechanism of polyglutamine diseases. In animal models, a polyQ stretch is sufficient for pathology and aggregation when inserted into a larger protein (Ordway et al., 1997) or as an independent peptide (Marsh et al., 2000) . In this model, the rest of the protein influences only the details of the death and dysfunction.
More recently, however, the protein context has been shown to be critical, and in some cases polyQ expansion by itself is not sufficient for disease. For instance, phosphorylation at serine 421 (Humbert et al., 2002) or serines 13 and 16 (Gu et al., 2009) SBMA is an X-linked neurodegenerative disease characterized by late-onset muscle weakness and wasting and degeneration of motor neurons in the brainstem and spinal cord (Orr and Zoghbi, 2007) . The polyQ expansion in SBMA occurs in the androgen receptor (AR), a classic nuclear hormone receptor. This makes SBMA one of the few polyQ diseases in which the function of the host protein is well understood. Nedelsky et al. (2010) combine existing knowledge about the AR with the power of fly genetics to home in on the source of polyQ toxicity. The authors expressed the human AR with wild-type (12Q) or pathogenic (52Q) glutamine stretches in the adult Drosophila eye or larval salivary glands and motor neurons. In agreement with previous findings, ligand binding and nuclear translocation were necessary to evoke the degenerative phenotype (Katsuno et al., 2002; Takeyama et al., 2002) . Nuclear translocation alone was insufficient; DNA binding was necessary to cause degeneration. Thus, the first steps of normal AR function are necessary for toxicity.
After DNA binding, the AR normally recruits transcriptional coregulators via its AF-1 and AF-2 domains. Preventing normal AF-2 interaction with coregulators rescued the toxicity of mutant AR, suggesting that normal AR-coregulator interactions are necessary for disease. Overexpression or knockdown of a specific coregulator known to bind at the AF-2 domain significantly affected the degenerative phenotype. The authors conclude that the polyQ expansion in the AR mediates toxicity via normal AR interactions. Which interactions are most important for toxicity and their pathogenic mechanism(s) remain unresolved.
How might normal interactions cause toxicity? Two observations suggest that toxicity is caused by enhanced AR activity. First, high levels of expression of wild-type AR showed a similar, yet more minor, degenerative phenotype, implying that high levels of normal AR activity, even in the absence of the polyQ expansion, are sufficient to cause degeneration. Second, gene expression profiling showed that expression of the wild-type AR yielded changes similar to those evoked by the mutant AR but to a lesser degree. The similarity in gene expression changes argues that the mild degenerative phenotype seen in flies expressing wild-type AR at high levels is not due to a nonspecific toxicity of overexpression. These data implicate polyQ-mediated enhanced activity of wild-type function as the source of toxicity in SBMA.
Independent work in this issue by Duvick et al. (2010) on the polyQ disease spinocerebellar ataxia type 1 (SCA1) arrives at a similar conclusion. SCA1 is caused by a polyQ-expanded version of the protein ataxin-1 and usually presents in middle age as progressive ataxia, tremor, and dysarthria. Pathology is characterized by marked cerebellar atrophy with Purkinje cell death (Orr and Zoghbi, 2007) . Protein context is also important in SCA1: phosphorylation at serine 776 of ataxin-1 is necessary for toxicity (Emamian et al., 2003) . Mutant ataxin-1 alters the balance of protein-protein interactions between itself and two binding partners, but abolishing phosphorylation at S776 restores the wild-type equilibrium (Lim et al., 2008) . Intriguingly, mimicking tonic phosphorylation by mutating serine to aspartic acid (S776D) causes wildtype ataxin-1 to interact with these binding partners as if it were polyQ expanded. Duvick et al. (2010) follow up on this finding to determine if wild-type ataxin-1-S776D can evoke dysfunction and pathology in vivo. They generated transgenic mice with Purkinje cell-specific expression of the wild-type (30Q) or mutant (82Q) ataxin-1 with the S776D mutation. Mice expressing ataxin-1-82Q demonstrated behavioral and histological pathology (Orr and Zoghbi, 2007) . Furthermore, the ataxin-1-82Q-S776D mice displayed similar pathology despite significantly less transgene expression, reflecting the enhanced toxicity of the mimicked tonic phosphorylation. The surprise came with analysis of the respective wild-type ataxin-1-30Q mouse lines. The ataxin-1-30Q-S776D cohort showed atrophy of Pukinje cell dendritic branches and a retraction of climbing fiber-Purkinje cell synapses, similar to that seen in those mice expressing mutant ataxin-1. The rotarod confirmed a progressive functional deficit. Hence, pathology caused by an expansion of a polyQ stretch was evoked in mice by the same protein with a nonmutant polyQ stretch if the phosphorylation site was mutated. It will be interesting to see if polyQ expansion facilitates phosphorylation at S776 in vivo.
If polyQ expansion is not necessary for ataxin-1 toxicity, then the wild-type functions of ataxin-1 alone might be sufficient for disease. Along these lines, mice expressing ataxin-1-30Q with no alteration at S776 showed evidence of pathology. This line has the highest transgene expression level, suggesting that excessive levels of normal ataxin-1 activity represent the GOF caused by polyQ expansion.
These two reports demonstrate that normal function of the host protein is crucial to pathogenesis in two distinct polyQ diseases and implicate excessive levels of normal function as the GOF that causes toxicity. Are there any reasons to worry that these model systems might not fully reflect the mechanisms at play in the human conditions? The AR has no direct ortholog in flies, so its interactions are occurring in a nonnative setting. However, the AF-1 and AF-2 domains are conserved in other native nuclear hormone receptors in Drosophila, and the majority of known human nuclear hormone coregulators have orthologs in the fly. Further, data from fly models of SBMA have been broadly consistent with those from mouse models (Katsuno et al., 2002; Takeyama et al., 2002) . It is also worth considering the increasing evidence of contributions to HD from cell types other than neurons expressing the polyQ expanded protein (Bradford et al., 2009) . If similar contributions are made in other polyQ diseases, then they might not be detected in the Drosophila eye or in a mouse with restricted transgene expression. Finally, any developmental contribution to disease, as has been suggested in the case of SCA1 (Orr and Zoghbi, 2007) , might be difficult to study.
Evidence for other causes of toxicity in these diseases exists. In SBMA, for example, patients can experience gynecomastia and hypogonadism, signs of mild androgen insensitivity. On the other hand, frank feminization is not observed, and loss of the AR does not cause neurodegeneration (Orr and Zoghbi, 2007) , arguing against LOF as In the conventional view, a protein with a polyQ stretch (hatched region) has a specific normal function. Expansion of the polyQ stretch causes disease due to an unrelated toxic gain of function (GOF) or a loss of normal function (LOF). Alternatively, distinct protein conformations exist in equilibrium. The equilibrium could be influenced in multiple ways, including chaperone binding (pink circle) and posttranslational modifications, such as phosphorylation (yellow circle). PolyQ expansion disturbs the equilibrium, leading to GOF associated with enhanced function of the stabilized conformer. There is also LOF due to decreased function associated with the less preferred conformer. The polyQ expansion could affect the equilibrium by stabilizing one of the conformers directly or by promoting an interaction with a conformation-specific binding partner (not depicted), or indirectly by reducing chaperone availability through stress on the proteostasis machinery. the sole cause of toxicity. A mixed GOF and LOF picture for SBMA may best explain patient phenotypes, consistent with in vitro data demonstating both upand downregulation of target genes by mutant AR expression (Lieberman et al., 2002) .
The studies discussed here provide clues as to how polyQ diseases could be explained by a dominant GOF together with a role for LOF (Figure 1) . The host protein might adopt one of several conformations that depend on specific posttranslational modifications, e.g., phosphorylation, with different conformations associated with particular functions. In the disease setting, polyQ expansion could stabilize certain conformations of the host protein at the expense of others, disrupting the equilibrium of protein conformations and enhancing the functions associated with certain conformations.
PolyQ expansions are also known to place an extra burden on the protein folding machinery (Powers et al., 2009 ). Thus, disease might occur through disrupted folding of other metastable proteins, contributing to their LOF. However, it is possible to imagine that the burden on the chaperone system could cause disease by enhancing a normal function of the instigating polyQ protein. A reduced availability of chaperones could shift the distribution of the host protein's conformers toward those that do not require chaperones (Figure 1) . The increase in the function that corresponds to that conformer would represent a GOF. Together, these changes might bring about cell dysfunction and eventual death.
These findings open the door to new therapeutic opportunities. There are no effective treatments for the polyQ diseases, and the seemingly promising approach of chemical castration for SBMA failed a recent clinical trial (Katsuno et al., 2010) . These studies suggest that targeting specific native protein functions may be required for effective treatment.
